Pharmaceuticals
We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.
We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising.
Explore our sectors
News and insights
News: 09 February 2024
Allen & Overy advises Sartorius group on EUR1.4bn equity raising
Frankfurt am Main - Allen & Overy has advised the Sartorius group on equity raisings with a total volume of EUR1.4bn. The transaction comprised the placement of 613,497 preference shares currently…
News: 09 February 2024
Allen & Overy advises Exponent on investment in Chanelle Pharma
LONDON – Allen & Overy (A&O) has advised Exponent Private Equity LLP (Exponent), a leading European private equity firm, on its investment in Ireland's largest manufacturer of generic pharmaceuticals,…
Blog Post: 02 February 2024
The European Commission (EC) has published its latest report on competition enforcement in medicines and medical products.
Blog Post: 12 January 2024
Senate Bill Introduced to Examine Bayh-Dole Reporting Requirements
On January 10, 2024, Senators Chris Coons and Thom Tillis introduced a bill titled Improving Efficiency to Increase Competition Act (“IEICA”). The IEICA would require that the Comptroller General…